The most widely used parameter for the selection of patients to be treated with immunotherapy is the immunohistochemical (IHC) evaluation of PD-L1 expression on both tumor and immune cells, given the higher response rate in patients with PD-L1 positive tumors in multiple clinical trials (7). The gene discussed is CD274; the disease is neoplasm.